ESMO-BC 2023
May 11 - 13, 2023 | Berlin, Germany
The agents listed below are currently under investigation. Their safety and efficacy have not been established.
Poster
TACTIVE-N: Open-Label, Randomized, Noncomparative Neoadjuvant Phase 2 Study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, or Anastrozole in Postmenopausal Women with ER+/Human Epidermal Growth Factor Receptor 2 (HER2)-Localized Breast CancerPA Fasching et al.
Poster
VERITAC Update: Phase 2 Study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader in ER+/Human Epidermal Growth Factor Receptor 2 (HER2)-Advanced Breast CancerSA Hurvitz et al.
Poster
TACTIVE-E: Phase 1b Study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, in Combination with Everolimus in ER+/Human Epidermal Growth Factor Receptor 2 (HER2)-Advanced Breast CancerA Philipovskiy et al.
Poster
VERITAC-2: A Global, Randomized Phase 3 Study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, vs Fulvestrant in ER+/Human Epidermal Growth Factor Receptor 2 (HER2)-Advanced Breast CancerEP Hamilton et al.